poisar

Stocks · News reference

If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today

BenzingaAug 27, 2026, 10:30 PMBenzinga Insights

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals has a market

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 27, 2026, 10:30 PM
Checked
Aug 27, 2026, 10:30 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolAug 28, 2026, 3:31 PMBrendan Coffey

    Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals?

    The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with a lower 0.35% expense ratio and concentrated biotech focus, versus Invesco Pharmaceuticals ETF (PJP) with higher dividend yield and broader pharma exposure. Despite PJP's superior 5-year performance and lower volatility, the article concludes BBH is the better buy based on recent outperformance, though both funds offer targeted healthcare sector exposure with different risk-return profiles.

    Read original at the-motley-fool
  2. The Motley FoolAug 21, 2026, 11:02 AMAndy Gould

    IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?

    The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.

    Read original at the-motley-fool